Endo intros generic Noxafil

Posaconazole injection is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections.

Sandra Levy

6/29/2023

Endo’s Par Sterile Products business has begun shipping posaconazole injection (18 mg/ml), which is the first generic version of Merck's Noxafil.

"We're pleased to provide choices to healthcare providers," said Scott Sims, senior vice president and general manager of injectable solutions and generics at Endo. "The first generic version of Noxafil injection does just that, while also strengthening our product portfolio and underscoring our reputation as a reliable, quality supplier."

Posaconazole injection is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia (low white blood cell counts) from chemotherapy.

[Read more: Par launches generic Pylera]

Noxafil vial had a market value of approximately $25 million for the 12 months ended May 31, 2023, per IQVIA.

Related Topics